Pharmacokinetic/Pharmacodynamic (PK/PD) Studies of Methylphenidate Extended Release Products in Attention Deficit Hyperactivity Disorder (ADHD) Patients (U01)

Funding Opportunity RFA-FD-14-015 from the NIH Guide for Grants and Contracts. The purpose of this project is to conduct a prospective PK/PD study in attention deficit hyperactivity disorder (ADHD) patients to link the PK profiles to the time-course of PD activity of methylphenidate extended release products in order to identify additional PK metrics (if any) that may impact the therapeutic equivalence of methylphenidate extended release products. The findings from the PK/PD study will help establish scientific and regulatory standards for assuring therapeutic equivalence of generic methylphenidate extended release products.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding

Related Links:

Translational Psychiatry, Published online: 15 November 2019; doi:10.1038/s41398-019-0619-yAdult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11C]methylreboxetine positron emission tomography study
Source: Translational Psychiatry - Category: Psychiatry Authors: Source Type: research
AbstractPurpose of ReviewAttention deficit hyperactivity disorder and methamphetamine use disorder are common comorbidities. National data regarding methamphetamine use is available per the most recent SAMSHA report. Even though attention deficit hyperactivity disorder and methamphetamine seem to commonly coexist, we do not have national figures which would provide a more comprehensive picture. The purpose of the article is to highlight this comorbidity and discuss some of the possible shared neurobiological and other pertinent overlapping features.Recent FindingsPer the 2017 SAMSHA report, among the 8.3 million younger ad...
Source: Current Developmental Disorders Reports - Category: Child Development Source Type: research
Publication date: Available online 12 November 2019Source: NeuroImageAuthor(s): Juha Salmi, Mostafa Metwaly, Jussi Tohka, Kimmo Alho, Sami Leppämäki, Pekka Tani, Anniina Koski, Tamara Vanderwal, Matti LaineAbstractIndividuals with attention-deficit/hyperactivity disorder (ADHD) have difficulties navigating dynamic everyday situations that contain multiple sensory inputs that need to either be attended to or ignored. As conventional experimental tasks lack this type of everyday complexity, we administered a film-based multi-talker condition with auditory distractors in the background. ADHD-related aberrant brain r...
Source: NeuroImage - Category: Neuroscience Source Type: research
CONCLUSION: This case report suggests that health and wellness coaching can be effective in supporting beneficial outcomes and can be useful in the multimodal management of ADHD. PMID: 31710834 [PubMed - in process]
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
The fate of a local company ’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. If granted, that could mean gettin g the treatment to patients in the second half of 2020. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Up to 60% of children with Attention-Deficit/Hyperactivity Disorder (ADHD) meet diagnostic criteria for at least one anxiety disorder, including Social, Generalized and/or Separation Disorder. Anxiety in child...
Source: BMC Psychiatry - Category: Psychiatry Authors: Tags: Study protocol Source Type: research
The fate of a local company ’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. If granted, that could mean gettin g the treatment to patients in the second half of 2020. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Abstract Sluggish cognitive tempo (SCT) appears to be distinct from attention-deficit/hyperactivity disorder (ADHD) and unique patterns of association between SCT and comorbid symptoms have been reported in the literature. The current study examined the relation between environmental supports and comorbid concerns among children with high SCT. Parents of children (ages 6-12) with a diagnosis of ADHD and clinically elevated SCT (N = 126) completed measures of emotional/behavioral functioning, child routines, and parental adjustment. Regression analyses revealed that after controlling for child age and...
Source: Child Psychiatry and Human Development - Category: Child Development Authors: Tags: Child Psychiatry Hum Dev Source Type: research
CONCLUSIONS: Differences in ADHD course - persistence, remission and late-onset - were not directly reflected in changes in IQ. Instead, having ADHD at any point across development was associated with lower average IQ and poorer executive functioning. Our finding that individuals with persistent ADHD have poorer response inhibition than those who remitted requires replication. PMID: 31718730 [PubMed - as supplied by publisher]
Source: Psychological Medicine - Category: Psychiatry Authors: Tags: Psychol Med Source Type: research
Translational Psychiatry, Published online: 13 November 2019; doi:10.1038/s41398-019-0614-3Motor cortex facilitation: a marker of attention deficit hyperactivity disorder co-occurrence in autism spectrum disorder
Source: Translational Psychiatry - Category: Psychiatry Authors: Source Type: research
More News: ADHD | Concerta | Contracts | Funding | Grants | Hyperactivity | Methylphenidate | Research | Ritalin | Study